Lyme Disease Diagnostics Market: By Emerging Diagnostic Technology (Serological Test (ELISA, Western Blot), Urine Antigen Tests, Lymphocytic Transformation Test, Immunofluorescent Stanning, Nucleic acid Test), By End-Users (Hospitals, Public/Private Laboratories, Physicians’ Offices) and Geography

Lyme Disease Diagnostics Market size was valued at USD 3,564.9 million in 2023 and is poised to grow at a CAGR of 5.7% from 2024 to 2030. Lyme disease is a tick-borne illness caused by Borrelia burgdorferi, characterized by fever, headache, fatigue, and a distinctive erythema migrants rash. If not treated promptly with antibiotics, it can lead to serious complications affecting the joints, heart, and nervous system. According to the Centers for Disease Control and Prevention (CDC), approximately 476,000 Americans are diagnosed and treated for Lyme disease each year. This high disease burden underscores the need for efficient diagnostic tools.

Technological advancements play a crucial role in market expansion, with innovations such as multiplex PCR assays and improved immunoassays enhancing the accuracy and speed of Lyme disease detection. These developments are critical in addressing the challenges of early-stage diagnosis and reducing false-negative results. Furthermore, growing public awareness about the long-term complications of untreated Lyme disease has led to increased demand for testing. This awareness, coupled with expanded healthcare expenditure and a focus on preventive care in many countries, further propels market growth. The market is also benefiting from increased healthcare expenditure and a growing focus on preventive care in many countries. The market faces challenges, including the complexity of lyme disease diagnosis, potential for false-negative results in early stages, and limited healthcare access in some rural endemic areas. Additionally, the high cost of advanced diagnostic equipment and the need for skilled technicians may hinder market growth in certain regions. North America region held the major market share in 2023 and is expected to dominate the global Lyme Disease Diagnostics Market in the forecasted years.

Lyme Disease Diagnostics Market Key Developments:

On April 13, 2022, Quidel Corporation, a healthcare diagnostics company, formed an association with the Bay Area Lyme (BAL) Foundation,

• Bay Area Lyme (BAL) Foundation is an organization dedicated to making Lyme disease easy to diagnose and simple to cure through research funding and education.
• Association was formed to educate people about their health, with a specific emphasis on Lyme disease awareness.